Raymond James & Associates’s MiMedx Group MDXG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $84.2K | Sell |
14,242
-1,017
| -7% | -$6.74K | ﹤0.01% | 3802 |
|
|
2024
Q2 | $106K | Buy |
15,259
+3,005
| +25% | +$21.1K | ﹤0.01% | 3723 |
|
|
2024
Q1 | $94.4K | Sell |
12,254
-716
| -6% | -$5.75K | ﹤0.01% | 3740 |
|
|
2023
Q4 | $114K | Buy |
+12,970
| New | +$95K | ﹤0.01% | 3632 |
|
|
2023
Q3 | – | Sell |
-51,314
| Closed | -$339K | – | 3880 |
|
|
2023
Q2 | $339K | Sell |
51,314
-4,100
| -7% | -$20.9K | ﹤0.01% | 3171 |
|
|
2023
Q1 | $189K | Hold |
55,414
| – | – | ﹤0.01% | 3505 |
|
|
2022
Q4 | $154K | Buy |
55,414
+4,100
| +8% | +$12.3K | ﹤0.01% | 3530 |
|
|
2022
Q3 | $147K | Sell |
51,314
-600
| -1% | -$2.13K | ﹤0.01% | 3526 |
|
|
2022
Q2 | $180K | Buy |
51,914
+42
| +0.1% | +$164 | ﹤0.01% | 3537 |
|
|
2022
Q1 | $244K | Sell |
51,872
-5,336
| -9% | -$26.1K | ﹤0.01% | 3552 |
|
|
2021
Q4 | $346K | Buy |
57,208
+680
| +1% | +$4.72K | ﹤0.01% | 3356 |
|
|
2021
Q3 | $343K | Sell |
56,528
-37,395
| -40% | -$421K | ﹤0.01% | 3321 |
|
|
2021
Q2 | $1.18M | Sell |
93,923
-53,410
| -36% | -$578K | ﹤0.01% | 2477 |
|
|
2021
Q1 | $1.52M | Buy |
147,333
+73,903
| +101% | +$714K | ﹤0.01% | 2212 |
|
|
2020
Q4 | $667K | Buy |
+73,430
| New | +$529K | ﹤0.01% | 2610 |
|
|
2018
Q4 | – | Sell |
-161,109
| Closed | -$996K | – | 3637 |
|
|
2018
Q3 | $996K | Sell |
161,109
-4,400
| -3% | -$19.9K | ﹤0.01% | 2262 |
|
|
2018
Q2 | $1.06M | Buy |
165,509
+3,991
| +2% | +$28.4K | ﹤0.01% | 2168 |
|
|
2018
Q1 | $1.13M | Sell |
161,518
-17,284
| -10% | -$201K | ﹤0.01% | 2046 |
|
|
2017
Q4 | $2.25M | Sell |
178,802
-33,966
| -16% | -$414K | ﹤0.01% | 1619 |
|
|
2017
Q3 | $2.53M | Buy |
212,768
+35,860
| +20% | +$532K | 0.01% | 1481 |
|
|
2017
Q2 | $2.65M | Buy |
176,908
+1,425
| +0.8% | +$19K | 0.01% | 1398 |
|
|
2017
Q1 | $1.67M | Buy |
175,483
+175
| +0.1% | +$1.48K | ﹤0.01% | 1646 |
|
|
2016
Q4 | $1.55M | Sell |
175,308
-9,100
| -5% | -$81.8K | ﹤0.01% | 1648 |
|
|
2016
Q3 | $1.58M | Buy |
184,408
+2,300
| +1% | +$18.2K | ﹤0.01% | 1604 |
|
|
2016
Q2 | $1.45M | Sell |
182,108
-10,800
| -6% | -$84K | ﹤0.01% | 1515 |
|
|
2016
Q1 | $1.69M | Buy |
192,908
+30,700
| +19% | +$255K | 0.01% | 1373 |
|
|
2015
Q4 | $1.52M | Sell |
162,208
-4,600
| -3% | -$39.9K | 0.01% | 1411 |
|
|
2015
Q3 | $1.61M | Buy |
166,808
+47,250
| +40% | +$499K | 0.01% | 1335 |
|
|
2015
Q2 | $1.39M | Buy |
119,558
+44,458
| +59% | +$457K | 0.01% | 1550 |
|
|
2015
Q1 | $781K | Buy |
75,100
+52,100
| +227% | +$488K | ﹤0.01% | 1804 |
|
|
2014
Q4 | $265K | Buy |
+23,000
| New | +$227K | ﹤0.01% | 2154 |
|
Other funds holding MDXG
EWM
TI
PCMI
CC
PAIM
Raymond James & Associates's MDXG Position: Q3 2024 in Review
Raymond James & Associates reduced its MiMedx Group (MDXG) stake by 6.7% in Q3 2024, selling an estimated $6.74K and leaving 14,242 shares worth $84.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3802.
Raymond James & Associates first reported a position in MDXG in Q4 2014 and has held it in 31 quarters since. The position peaked at $2.65M in Q2 2017. 194 funds tracked by Wall St. Rank hold MDXG as of Q3 2024.
- Raymond James & Associates held 14,242 shares of MiMedx Group worth $84.2K as of Q3 2024.
- Raymond James & Associates sold 1,017 MiMedx Group shares in Q3 2024, an estimated $6.74K.
- MiMedx Group made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3802 holding.
- Raymond James & Associates first reported a position in MiMedx Group in Q4 2014 and has held it in 31 quarters since.
- Raymond James & Associates's MiMedx Group position peaked at $2.65M in Q2 2017.
- 194 funds tracked by Wall St. Rank held MiMedx Group as of Q3 2024.
Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.